Rita Balsano

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

N/A

0Author DataRank · unranked

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population”.

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

European Journal of Cancer(2024)10.1016/j.ejca.2024.114199

N/A

0.578DataRank · unranked

46 citations

Lorenzo Fornaro, Mario Domenico Rizzato, Lorenzo Antonuzzo, Federico Rossari, Tomoyuki Satake +56 more

Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?

Tumori Journal(2022)10.1177/03008916221132589

N/A

0.269DataRank · unranked

5 citations

Rita Balsano, Fabio Gelsomino, Francesco Leonardi, Ingrid Garajová